A recent study identifies a new biochemical mediator potentially able to represent a marker of neurodegeneration in Huntington's disease, Alzheimer's disease and Parkinson's disease.
20/01/2021
The first two Italian patients started the trial today, January 20, 2021, in Rome, at the CSS-Mendel Institute, section of IRCCS Casa Sollievo della Sofferenza and Coordinating Center for Italy, under the guidance of Principal Investigator Prof. Ferdinando Squitieri.
15/01/2021
COVID-19 quickly disrupted customary clinical practices. Within few weeks, as quarantine and social distancing became the norm, in-person medical appointments became increasingly sporadic and were replaced by those conducted with audiovisual tools. In doing so, telemedicine, hitherto on the margins, became protagonist.
24/11/2020
In an official statement of 17 November 2020, PTC Therapeutics announced the initiation of a Phase 1 clinical trial to evaluate PTC518 in healthy volunteers. The Phase 1 study includes both single and multiple ascending dosing regimens that will help establish the safety, pharmacology, and dose selection for the Phase 2 study.
13/11/2020
A recent study published in “Experimental Brain Research”, a journal of the Nature Group, investigates the relationship between the ability to visually scan and the difficulty of recognizing others’ emotions, in the pre-symptomatic phase of Huntington's disease (preHD). Why is this important?
29/10/2020
23/10/2020
14/10/2020
25/09/2020
The SIGNAL trial began in 2015 in 20 centers across the United States, involving 301 patients with Huntington's disease in the early stages or not yet symptomatic .
The study was designed to test whether a drug called pepinemab(also known as VX15) produced by Vaccinex, was safe for people with HD, and whether it could slow the effects of HD, like changes to the brain, and difficulties with thinking, movements, and behavior.
21/09/2020
On the last September 16th and 17th 2020 we took part in the 'c4c Workshop for Patients and Patient Organizations' addressing aspects related to the ethical implications and regulatory aspects of children and young people (CYP) involvement in clinical trials. We also had the opportunity to discuss the methodology behind the design and the carrying out of a clinical trial, as well as the structure and contents of research protocols.
